This article reviews the pertinent studies regarding paclitaxel combined with cisplatin or carboplatin , discusses the remaining controversies surrounding how best to combine these agents , and provides opinions regarding the discordant outcomes noted in studies of the paclitaxel-platinum doublet .
Current status of taxane and platinum-based chemotherapy in ovarian cancer. Before 1993, the standard of care for the chemotherapeutic management of advanced ovarian cancer was cisplatin or carboplatin combined with a classic alkylating agent (typically cyclophosphamide). Studies in the 1990s have changed this standard to one of the platinum-containing agents combined with a taxane, paclitaxel, or docetaxel. This article reviews the pertinent studies regarding paclitaxel combined with cisplatin or carboplatin , discusses the remaining controversies surrounding how best to combine these agents , and provides opinions regarding the discordant outcomes noted in studies of the paclitaxel-platinum doublet . A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Current status of taxane and platinum-based chemotherapy in ovarian cancer. Before 1993, the standard of care for the chemotherapeutic management of advanced ovarian cancer was cisplatin or carboplatin combined with a classic alkylating agent (typically cyclophosphamide). Studies in the 1990s have changed this standard to one of the platinum-containing agents combined with a taxane, paclitaxel, or docetaxel. This article reviews the pertinent studies regarding paclitaxel combined with cisplatin or carboplatin , discusses the remaining controversies surrounding how best to combine these agents , and provides opinions regarding the discordant outcomes noted in studies of the paclitaxel-platinum doublet . A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer.

            ### Response:
            paclitaxel, cisplatin, carboplatin
            